[et_pb_section fb_built=”1″ admin_label=”Section” _builder_version=”3.22″ collapsed=”off” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.12.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ collapsed=”off” global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.12.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”]
Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?
PERSPECTIVE article
Front. Hum. Neurosci., 18 June 2024
Sec. Speech and Language
Volume 18 – 2024 | https://doi.org/10.3389/fnhum.2024.1402549
Giuseppe Pasculli, Pierpaolo Busan, Eric S. Jackson, Per A. Alm, Danilo De Gregorio, Gerald A. Maguire, Guy M. Goodwin, Gabriella Gobbi, David Erritzoe and Robin L. Carhart-Harris
Developmental stuttering (DS) is a neurodevelopmental speech-motor disorder characterized by symptoms such as blocks, repetitions, and prolongations. Persistent DS often has a significant negative impact on quality of life, and interventions for it have limited efficacy. Herein, we briefly review existing research on the neurophysiological underpinnings of DS -specifically, brain metabolic and default mode/social-cognitive networks (DMN/SCN) anomalies- arguing that psychedelic compounds might be considered and investigated (e.g., in randomized clinical trials) for treatment of DS.
Read the article here: https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2024.1402549/full?utm_source=F-NTF&utm_medium=EMLX&utm_campaign=PRD_FEOPS_20170000_ARTICLE
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
